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Abstract
Background: The metabolic syndrome (MetS), as well as postprandial hypertriglyceridemia, is
associated with coronary heart disease. This study aimed to evaluate the postprandial lipemia after
oral fat tolerance test (OFTT) in subjects with MetS and compare them to hypertensive (HTN) and
healthy subjects.
Results: OFTT was given to 33 men with MetS (defined by the Adult Treatment Panel III), 17 HTN
and 14 healthy men. The MetS group was further divided according to fasting triglycerides (TG)
into TG ≥ 150 [MetS+TG, (n = 22)] or <150 mg/dl [MetS-TG (n = 11)], and into those with or
without hypertension [MetS+HTN (n = 24), MetS-HTN (n = 9), respectively]. TG concentrations
were measured before and at 4, 6 and 8 h after OFTT and the postprandial response was quantified
using the area under the curve (AUC) for TG.
The postprandial response was significantly higher in MetS compared to HTN and healthy men
[AUC (SD) in mg/dl/h; 2534 ± 1016 vs. 1620 ± 494 and 1019 ± 280, respectively, p ≤ 0.001]. The
TG levels were increased significantly in MetS+TG compared to MetS-TG subjects at 4 (p = 0.022),
6 (p < 0.001) and 8 hours (p < 0.001). The TG were increased significantly in MetS-TG compared
to healthy subjects at 4 (p = 0.011), 6 (p = 0.001) and 8 hours (p = 0.015). In linear regression
analysis only fasting TG levels were a significant predictor of the AUC (Coefficient B = 8.462, p <
0.001).
Conclusion: Fasting TG concentration is the main determinant of postprandial lipemia. However,
an exaggeration of TG postprandialy was found in normotriglyceridemic MetS and HTN compared
to healthy subjects. This suggests that intervention to lower fasting TG levels should be
recommended in MetS subjects.
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In 1988, Reaven et al. proposed insulin resistance as the
underlying metabolic aberration linking essential hyper-
tension (HTN), dyslipidemia, type 2 diabetes and other
abnormalities associated with an increased risk of athero-
sclerotic cardiovascular disease in adults [1]. This constel-
lation is now designated as the metabolic syndrome
(Mets). Since then, many epidemiological studies have
shown that MetS is associated with an increased incidence
of coronary heart disease (CHD) [2,3]. MetS is clinically
characterized by the presence of abnormal fasting triglyc-
eride (TG) levels, low high-density lipoprotein (HDL)
cholesterol levels, elevated plasma glucose, HTN and
abdominal obesity. However, according to the National
Cholesterol Education Program – Adults Treatment Panel
(ATP III) guidelines, the diagnosis of MetS is present when
at least three of the above five clinical criteria co-exist [4].
Although estimates of the prevalence are critically
dependent on the exact definition used, the MetS has
reached epidemic proportions. The age-adjusted preva-
lence of the MetS in the United States is estimated at 24%
and increases to 44% in adults who are over 60 years old
[5]. Similar results were found in Greek population
(19.8%) [6].
Postprandial hypertriglyceridemia is also associated with
cardiovascular disease [7]. During the postprandial state,
TG rich lipoproteins such as chylomicrons, very low-den-
sity lipoproteins and their remnants, may promote the
development of atherogenic small dense low-density lipo-
protein (LDL) particles [8]. Abnormal postprandial
lipemia has been observed in normolipidemic men with
or without CHD [9], in heterozygous familial hypercho-
lesterolemia (hFH), in women with CHD, in hyperten-
sives and others, according to previous studies including
ours [10-14]. Only few data exist regarding the response
of TG to fatty meal in subjects with MetS [15]. The aim of
this study was to evaluate the postprandial lipemia after
an oral fat tolerance test (OFTT) in patients with MetS
(defined by ATP III).
Results
All participants ingested their fatty meal and tolerated it
well. The amount of fatty meal ingested by the MetS group
was 362(28) g, by the HTN was 333(23) g, and by the
Healthy was 347(16) g.
Clinical Characteristics
Clinical characteristics of main groups (MetS, HTN, and
Healthy) are shown in Table 1. Clinical characteristics of
subgroups (MetS+HTN, MetS-HTN, MetS+TG and MetS-
TG) are shown in Table 2.
Postprandial Changes
Plasma total and HDL cholesterol, apolipoproteins A and
B, and lipoprotein (a) were measured postprandialy in a
60% of the study population and no significant difference
was found between groups.
The following changes were noticed pre and post OFTT:
A) Comparison of the TG concentrations at 0, 4, 6, 8 h in
MetS, HTN and Healthy subject groups are shown in
Figure 1. Schematic representation of postprandial
response (AUC) of the above three groups is shown in Fig-
ure 2.
B) In MetS+HTN and HTN groups: The TG levels were sig-
nificantly increased in MetS+HTN vs. HTN subjects at 4
hours (p = 0.022), 6 (p < 0.001) and 8 hours (p < 0.001).
[Mean (SD) values are presented in Table 1, 2].
C) In MetS+TG and MetS-TG: The TG levels were increased
significantly in MetS+TG vs. MetS-TG subjects at 4 (p =
0.022), 6 (p < 0.001) and 8 hours (p < 0.001). [Mean (SD)
values are presented in Table 2].
D) In MetS-TG and Healthy: The TG levels were increased
significantly in MetS-TG vs. Healthy subjects at 4 (p =
0.011), 6 (p = 0.001) and 8 hours (p = 0.015). [Mean (SD)
values are presented in Table 1, 2].
E) No significant differences were found in MetS+HTN vs.
MetS-HTN and in MetS-TG vs. HTN subjects.
F) In linear regression analysis, where the AUC was the
dependent variable and age, body mass index (BMI), HDL
cholesterol, fasting TG, fasting glucose and HOMA-IR
were the independent variables, only fasting TG levels
were independently associated with high AUC values
(Coefficient B = 8.462, p < 0.001).
Discussion
In the present study we investigated the effect of a fatty
meal on plasma TG concentration in untreated men with
MetS, HTN and Healthy. We showed that MetS men have
a different response to a fatty meal when compared to
HTN and Healthy men. Linear regression analysis showed
that for every rise of 1 mg/dl of the fasting TG values, the
AUC increased by 8.462 mg/dl/h.
The fasting TG values were 129% higher in MetS com-
pared to Healthy men. The observed difference was
smaller than that reported by Chan et al [16]. Several facts
could explain this difference: First, the fasting TG levels in
their control group were much lower compared to our
group. Fasting TG levels of their MetS subjects were also
lower even though the BMI was higher. Indeed, when thePage 2 of 8
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jects, the fasting TG values did not differ substantially
[17]. Furthermore, the regulation of plasma TG in MetS
men may differ according to concomitant characteristics.
An enhanced TG rise postprandialy has been reported not
only in patients with CHD [18], but also in patients with
diabetes mellitus [19] and obesity [20], all of which are
common findings in MetS subjects.
Obesity is associated with a range of metabolic abnormal-
ities including fasting and postprandial dyslipidemia.
This point is considered in greater detail; see our review
[21]. In summary, visceral adiposity with increased intra-
abdominal fat has been shown to precede the develop-
ment of insulin resistance. The insulin resistance is associ-
ated with dyslipidemia [22] and may affect chylomicron
remnant metabolism by down regulating LDL-receptor
expression and increasing hepatic cholesterol synthesis
and very low-density lipoprotein secretion [23]. These
effects increase competition between chylomicron and
very low density lipoprotein remnants for hepatic recep-
tors, thereby impairing the uptake of chylomicron rem-
nants by this pathway [24]. These changes result in
elevated postprandial TG levels. Obesity has similar
potential effects on chylomicron remnant metabolism.
However, a weight reduction of 10 kg in insulin-resistant
obese men was insufficient to reduce the elevated chylom-
icron remnant levels [25]. In contrast, type 2 diabetic
patients treated with insulin, showed a 28% decrease in
fasting plasma TG levels, a 17% increase in total HDL cho-
lesterol, while the magnitude of postprandial lipemia
after the ingestion of fatty meal decreased by 38%. Addi-
tionally, insulin treatment was accompanied by a 21%
increase in lipoprotein lipase activity and a 20% increase
in cholesteryl ester transport protein activity [26].
Essential hypertension constitutes one of the features
included in the MetS and is further associated with insulin
resistance. We have previously reported [13] that hyper-
tension is associated with an abnormal response to a fatty
meal (increased TG levels and delayed TG clearance),
which seems to aggravate the prognosis of hypertensive
patients. In our current subjects with MetS and hyperten-
sion (24 out of 33 MetS subjects) the exaggerated post-
Table 1: Clinical characteristics of the 3 main study groups.
Characteristics MetS n = 33 HTN n = 17 Healthy n = 14 P values
Age (years) 50(11) 52(10) 49(9) 0.632
BMI (kg/m2) 30(4) 26(2) 26(2) <0.001
Waist (cm) 107(11) 93(5) 95(6) <0.001
CHD -/+ 25/8 17/0 14/0
Hypertension -/+ 9/24 0/17 14/0
Systolic BP (mmHg) 141(19) 149(18) 121(7) <0.001
Diastolic BP (mmHg) 83(12) 92(11) 74(9) <0.001
Smokers -/+ 12/21 9/8 14/0
Diabetes mellitus -/+ 26/7 16/1 14/0
TC (mg/dl) 241(39) 214(29) 188(28) <0.001
HDL (mg/dl) 35(7) 48(15) 51(15) <0.001
LDL (mg/dl) 165(36) 145(31) 113(33) <0.001
Apo A (mg/dl) 133(19) 148(30) 159(48) 0.038
Apo B (mg/dl) 137(28) 124(23) 125(29) 0.232
Lp (a) (mg/dl) 16(13) 21(16) 16(11) 0.57
Glucose (mg/dl) 109(29) 93(10) 91(10) 0.013
Insulin (µU/ml) 14(9) 8(9) 7(5) 0.036
HOMA-IR 3.9(2.7) 2.1(2.2) 1.7(1.1) 0.015
TG0 (mg/dl) 204(86) 105(30) 89(30) <0.001
TG4 (mg/dl) 364(153) 242(84) 145(44) <0.001
TG6 (mg/dl) 366(155) 269(94) 142(53) <0.001
TG8 (mg/dl) 297(124) 200(87) 131(56) <0.001
AUC (mg/dl/h) 2534(1016) 1620(494) 1019(280) <0.001
All values are presented as means (standard deviation) or percentages for categorical variables. P values arose by ANOVA analysis and denote 
difference among the three groups. MetS: men with metabolic syndrome, HTN: Hypertensive men, BMI: body mass index, CHD: coronary heart 
disease, TC: total cholesterol, HDL: high-density lipoprotein cholesterol, LDL: low-density lipoprotein cholesterol, Apo: apolipoprotein, Lp: 
lipoprotein, TG0: fasting plasma triglyceride concentration, TG4, TG6, TG8: plasma triglyceride concentration 4, 6, 8 h after the fat load, 
respectively, HOMA-IR: index of homeostasis model of insulin resistance, AUC: area under the curve for triglycerides. To convert from mg/dl to 
mmol/L for TC, HDL, LDL, divide by 38.7. To convert from mg/dl to mmol/L for glucose, divide by 18. To convert from mg/dl to mmol/L for TG 
divide by 88.6.Page 3 of 8
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pronounced than in 17 subjects with hypertension as a
single abnormality [at 4 hours (p = 0.022), 6 (p < 0.001)
and 8 hours (p < 0.001)]. It is difficult to distinguish
which mechanism is responsible for this. The variability
of BMI or fasting TG levels between subjects with MetS
and hypertension compared to subjects with hyperten-
sion only [30(4) vs. 26(2), or 187(86) vs. 105(30), respec-
tively] can probably account for these differences.
However, other mechanisms may also be responsible.
In our current study HDL cholesterol levels were found to
be lower in the MetS subjects compared to Healthy men
as expected. However, other studies, including ours [27],
have suggested that the levels of HDL cholesterol do not
affect postprandial TG magnitude. Specifically, in a sub-
group of subjects with isolated low fasting HDL choles-
terol, fasting hypertriglyceridemia was a prerequisite in
order to have an exaggerated postprandial TG response
[28]. Additionally, Cohen and co-workers [29] measured
the response of plasma TG and retinyl palmitate to differ-
ent fatty meals in endurance-trained men with a wide
range of plasma HDL cholesterol concentrations (36–105
mg/dl). Their data indicated that the magnitude of post-
prandial lipemia is not primarily affected by HDL choles-
terol concentration.
The remnants of TG-rich lipoproteins accumulated in the
postprandial state are involved in atherogenesis. They act
as carriers of cholesteryl ester to the vessel wall and also
induce endothelial dysfunction with their toxic influence
on endothelial cells [30]. Furthermore, the
hypertriglyceridemic state is accompanied by small dense
LDL particles that are more susceptible to oxidation and
low concentrations of HDL cholesterol [31].
Hypertriglyceridemia may also be involved in events lead-
ing to thrombosis [32] and probably provoke activation
of nuclear factor kappa B, a proposed key mediator of
atherosclerosis [33]. In subjects with MetS, the hypertrig-
lyceridemia is one of the main lipid abnormalities, which
potentially is responsible for exaggerated TG postprandi-
aly. However, in subjects with MetS and normal fasting
TG [125(22) mg/dl], defined by ATP III guidelines (< 150
mg/dl), the TG levels postprandialy were exaggerated and
Table 2: Clinical characteristics of different subgroups.
Characteristics MetS+HTN MetS-HTN MetS-TG MetS+TG
Number of patients 24 9 11 22
Age (years) 53(10) 40(6) 52(10) 48(11)
BMI (kg/m2) 30(4) 31(3) 30(4) 30(4)
Waist (cm) 105(10) 115(10) 104(9) 108(11)
CHD -/+ 16/8 9/0 6/5 19/3
Hypertension -/+ 0/24 9/0 1/10 8/14
Systolic BP (mmHg) 148(17) 123(11) 143(12) 140(22)
Diastolic BP (mm Hg) 85(13) 78(6) 82(15) 83(11)
Smokers -/+ 10/14 2/7 4/7 8/14
Diabetes mellitus -/+ 17/7 9/0 7/4 19/3
TC (mg/dl) 234(37) 259(40) 228(34) 247(40)
HDL (mg/dl) 36(7) 30(3) 34(6) 35(7)
LDL (mg/dl) 159(34) 179(38) 166(33) 164(38)
Apo A (mg/dl) 137(19) 124(17) 130(10) 135(23)
Apo B (mg/dl) 135(29) 143(25) 134(36) 139(24)
Lp (a) (mg/dl) 16(11) 17(19) 16(10) 17(15)
Glucose (mg/dl) 113(33) 101(11) 114(35) 107(26)
Insulin (mg/dl) 12(6) 22(14) 14(9) 15(10)
HOMA 3.4(2.1) 5.8(3.9) 3.7(2.4) 4.1(2.9)
TG0 (mg/dl) 187(86) 248(72) 125(22) 243(78)
TG4 (mg/dl) 327(116) 454(199) 232(96) 411(143)
TG6 (mg/dl) 344(150) 426(161) 256(95) 421(151)
TG8 (mg/dl) 287(126) 321 (121) 200(73) 343(117)
AUC (mg/dl/h) 2349(945) 2984(1099) 1639(549) 2960(907)
All values are presented as means (standard deviation) or percentages for categorical variables. MetS: men with metabolic syndrome, HTN: 
Hypertensive men, BMI: body mass index, CHD: coronary heart disease, TC: total cholesterol, HDL: high-density lipoprotein cholesterol, LDL: 
low-density lipoprotein cholesterol, Apo: apolipoprotein, Lp: lipoprotein, TG0: fasting plasma triglyceride concentration, TG4, TG6, TG8: plasma 
triglyceride concentration 4, 6, 8 h after the fat load, respectively, HOMA-IR: index of homeostasis model of insulin resistance, AUC: area under the 
curve for triglycerides. To convert from mg/dl to mmol/L for TC, HDL, LDL, divide by 38.7. To convert from mg/dl to mmol/L for glucose, divide 
by 18. To convert from mg/dl to mmol/L for TG divide by 88.6.Page 4 of 8
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prandial response was similar in MetS subjects with
hypertension compared to MetS subjects with normal
blood pressure, even though the baseline TG levels were
lower in the former [187(86) vs. 248(72) mg/dl, p =
0.041, respectively]. This suggests that after certain fasting
TG levels, no further increase of postprandial TG occurs;
alternatively other mechanisms could be involved such as
genetic influence.
Conclusion
Our data indicate that fasting TG concentration is the
main determinant of postprandial lipemia. However, an
exaggeration of TG postprandialy is observed in MetS and
HTN subjects with normal fasting TG levels. This suggests
that intervention to lower fasting TG levels should be rec-
ommended in MetS subjects.
Methods
Study population
The study population consisted of 64 Greek men. Heavy
drinking, liver and renal disease, hypothyroidism, profes-
sional sport activity and the use of hypolipidemic drugs
were exclusion criteria. The study population was divided
into 3 groups:
1. The MetS group consisted of 33 men, mean age 50 ± 11
years. The diagnosis of MetS was based on the co-existence
of at least three of the following five clinical criteria: a)
abdominal obesity (waist >102 cm), b) serum TG levels ≥
150 mg/dl, c) serum HDL cholesterol levels <40 mg/dl, d)
blood pressure ≥ 130/85 mmHg, e) fasting glucose >110
mg/dl.
2. The Hypertensive (HTN) group consisted of 17 men,
mean age 52 ± 10 years with a negative CHD history.
Additionally, their serum TG levels were < 150 mg/dl, and
none of them fulfilled the criteria for MetS.
3. The Healthy group consisted of 14 healthy men, age-
matched, mean age 49 ± 9 years with no family history of
premature atherosclerosis, diabetes mellitus, HTN and
dyslipidemia. Their fasting TG levels were < 150 mg/dl,
their fasting glucose < 110 mg/dl, their total cholesterol <
240 mg/dl, their LDL <160 mg/dl, and their blood pres-
Comparison of triglyceride (TG) concentrations at 0, 4, 6, 8 h between pairs of the three main groups [men with metabolic syndrome (MetS), Hypert nsive me  (HTN) a d Healthy]Figure 1
Comparison of triglyceride (TG) concentrations at 0, 4, 6, 8 h between pairs of the three main groups [men with metabolic 
syndrome (MetS), Hypertensive men (HTN) and Healthy].Page 5 of 8
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smokers.
The MetS group was further divided into those with base-
line TG levels < 150 mg/dl (MetS-TG, n = 11) and into
those with TG levels ≥ 150 mg/dl (MetS+TG, n = 22), and
into MetS with and without HTN [MetS+HTN (n = 24)
and MetS-HTN (n = 9), respectively].
All participants gave their informed consent and the Eth-
ics Committee of the Onassis Cardiac Surgery Centre, Ath-
ens, Greece, approved the study protocol.
Study Protocol
All patients were studied in the outpatient clinic between
8.00–9.00 am after 12 h overnight fast. The fatty meal was
consumed within 20 min and plasma TG concentrations
were measured before and 4, 6 and 8 h after the fat load.
During this 8 h period, the participants did not eat and
did not smoke. They were only allowed to drink water.
Blood samples were drawn at 8:00 (before the meal), at
12:30 am (4 h after the meal), at 2:30 pm (6 h after the
meal), and at 4:30 pm (8 h after the meal). In all four sam-
ples total cholesterol, TG, HDL cholesterol, apolipopro-
teins A and B, and lipoprotein (a) were measured. The
content of the fatty meal has been described in a previous
study [13]. Briefly, the fatty meal was a slight modification
of that introduced by Patsch et al. [9], consisting of 83.5%
fat, 14.0% carbohydrates and 2.5% proteins and was
given in a dose based on the patient's body surface area
(350 g for 2 m2).
Determination of blood lipids and glucose
Plasma total cholesterol, TG and HDL cholesterol were
measured using enzymatic colorimetric methods on a
Roche Integra Biochemical analyzer with commercially
available kits (Roche Diagnostics Gmbh, Hannheim, Ger-
many). The serum LDL cholesterol levels were calculated
using the Friedewald formula [34] only in patients with
TG levels <400 mg/dl. Apolipoproteins A, B and lipopro-
Schematic representation of postprandial response (area under the curve) of the three main groups [men with metabolic syn-drome (MetS), Hyper ensive men (HTN) and Healthy]Figure 2
Schematic representation of postprandial response (area under the curve) of the three main groups [men 
with metabolic syndrome (MetS), Hypertensive men (HTN) and Healthy]. p = 0.001 for differences between MetS 
and HTN groups. p < 0.001 for differences between MetS and Healthy groups. p < 0.001 for differences between HTN and 
Healthy groups.Page 6 of 8
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eter: BN-100, Behring, Germany). Blood glucose was
measured by the hexokinase method with a Dade Behring
reagent on a Dimension (Dade Behring) instrument.
Blood insulin was measured with the IMX ABBOTT Diag-
nostics instrument. All samples were analyzed within 24
h.
The body mass index was calculated as weight divided by
height expressed in kg/m2. We assessed the whole-body
insulin resistance with the following formula: HOMA-IR
= (fast glucose × fast insulin)/22.5 [13].
Statistical Analysis
Categorical variables are presented as percentages. Values
of numerical characteristics were tested for normality and
are presented as mean value (± SD), if normally distrib-
uted. An ANOVA or Kruskal-Wallis H test with a Bonfer-
roni correction (whichever appropriate) was performed
for three group comparisons. The t-test for independent
samples or the Mann Whitney U test was used for the
comparison of numerical values between two groups.
Areas under the curve (AUC) for serial measurements of
TG levels at baseline and after the fatty meal were calcu-
lated using the trapezoid rule. Linear regression analysis,
where the AUC was the dependent variable and age, BMI,
HDL cholesterol, fasting TG, fasting glucose and HOMA-
IR were the independent variables was performed in order
to uncover the significant predictors of postprandial
lipemia (i.e. high AUC values). The level of significance
was set at p < 0.05.
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